Clinical Trial Title Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Trial Status Closed to Enrollment
Start Date 10/25/2017
Location Doctors & Locations
Trial Type Cancer - Adult Oncology
Specific Condition Grade II Meningioma
Description This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Eligibility Criteria
  • Histologically confirmed diagnosis of WHO grade II meningioma confirmed by central pathology review
  • Age ≥ 18
  • Post-operative Zubrod Performance Status 0-1 within 60 days
  • History/physical examination, including neurologic examination within 60 days
  • If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days

Ineligibility Criteria

  • Optic nerve sheath meningioma, spinal or other extracranial meningioma, multiple meningiomas, hemangiopericytoma
  • Definitive evidence of metastatic meningioma
  • Prior invasive malignancy unless disease free for a minimum of 3 years
  • Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas
  • Inability to undergo MRI with and without contrast

Please contact Legacy Oncology Research for additional study inclusion/exclusion information


IRB Number Central IRB
Principal Investigator Andrew Kee, MD
Contact Name Oncology Clinical Research
Contact Phone 503-413-8199
Contact Fax 503-413-6920
Contact E-Mail